Skip to content

The Prevalence of the Aortic to Radial Pressure Gradient in States of Shock, Outside the Context of Cardiac Surgery, a Prospective Study

Prevalence of the Aortic to Radial Pressure Gradient in States of Shock

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06460519
Acronym
PARECHOC
Enrollment
180
Registered
2024-06-14
Start date
2024-10-03
Completion date
2027-11-03
Last updated
2026-09-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Shock

Keywords

Radial artery, Femoral artery, Norepinephrine equivalent, Intensive care unit

Brief summary

First described in cardiac surgery, the aortic to radial pressure gradient (ATRAP) is the cause of an underestimation of the aortic pressure with a measure assumed with a radial catheter, and he can concert 1 of 3rd patients. The risks factor well known are small height, previous hypertension, long and difficult surgery, radial artery diameter less than 1.8mm. The ATRAP definition is a pressure difference between radial and femoral (same of the aortic pressure) pressure of 25mmHg on the systolic pressure, or a pressure difference on the mean pressure of 10mmHg, both measures realised by arterial canulation, and with a duration superior than 5 minutes. If this gradient appears in pathophysiological specifics situations, there is a risk of inappropriate administration of vasopressors, with more hospitalisation days, more side effect of vasopressors like an augmentation of myocardial work. The ATRAP is documented in septic shock with a prevalence between 21% and 27%. The ATRAP can appear in shocks, moreover with doses of equivalent norepinephrine of 0.5 µg/kg/min who is use for the definition of refractive shock, the difference between the two pressure is higher if the dose of equivalent norepinephrine is higher than 1µg/kg/min. But the prevalence and risks factors are barely unknowns in this situation. Most of the time, a radial arterial catheter is used for hemodynamic monitoring for his simplicity of utilisation and the lows complications associated. Some medical teams in cardiac surgeries, or in intensive care unit (ICU) for the management of shocks used often radial and femoral arterial catheter. It seems there is no at risk for the utilisation of a radial and femoral arterial canulation. Out of the situation of cardiac surgery, there is a lack of information of the ATRAP, the objective of the study is to evaluate the prevalence of the ATRAP in shock, out of the situation of cardiac surgery.

Interventions

OTHERNon-invasive blood pressure measurements

Non-invasive blood pressure measurements to the tension cuff three times in a row on each side (right arm and left arm)

Sponsors

Hospices Civils de Lyon
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No

Inclusion criteria

* age superior or equal 18 years * Vasopressors support superior or equal 0.5 µg/kg/min of equivalent norepinephrine * Invasive monitoring of blood pressure with a radial arterial catheter and a femoral arterial catheter decided by de physician * Beginning of the shock less than 48 hours. * Consent

Exclusion criteria

* perioperative of cardiac surgery (between the beginning of the surgery and 7 days after) * pregnant woman or breast-feeding * Major person under protection * Person with privation of liberty by a justice decision, or an administrative decision

Design outcomes

Primary

MeasureTime frameDescription
Prevalence (percentage) of ATRAP is determined by the ratio of patients with ATRAP to total. ATRAP is defined by a 25mmHg systolic or 10mmHg mean pressure difference between radial and femoral arterial pressures during more than 5 minutes.The primary outcome will be measure at the inclusion of the patient when the femoral arterial catheter will be in place.The prevalence of the ATRAP will be show in percentage (%), with his confidence interval at 95%.

Countries

France, Guadeloupe

Contacts

CONTACTMatthias Jacquet-lagreze, Dr
matthias.jacquet-lagreze@chu-lyon.fr0783426888
CONTACTMartin Ruste, Dr
martin.ruste@chu-lyon.fr0472118956

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 18, 2026